Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
AFFY [NASD]
Affymax, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.53 Insider Own0.54% Shs Outstand37.49M Perf Week4.51%
Market Cap52.11M Forward P/E- EPS next Y-1.12 Insider Trans17.40% Shs Float37.23M Perf Month44.79%
Income-93.41M PEG- EPS next Q-0.27 Inst Own54.74% Short Float34.72% Perf Quarter-42.56%
Sales94.37M P/S0.55 EPS this Y-39.43% Inst Trans-39.20% Short Ratio1.32 Perf Half Y-94.22%
Book/sh-0.39 P/B- EPS next Y40.50% ROA-78.76% Target Price0.67 Perf Year-90.19%
Cash/sh2.08 P/C0.67 EPS next 5Y7.00% ROE-221.68% 52W Range0.78 - 27.74 Perf YTD-92.68%
Dividend- P/FCF- EPS past 5Y0.00% ROI-158.55% 52W High-94.99% Beta1.10
Dividend %- Quick Ratio- Sales past 5Y16.31% Gross Margin- 52W Low78.21% ATR0.19
Employees304 Current Ratio1.03 Sales Q/Q302.47% Oper. Margin-97.50% RSI (14)55.23 Volatility14.04% 16.47%
OptionableYes Debt/Eq1.07 EPS Q/Q-122.74% Profit Margin-98.98% Rel Volume0.21 Prev Close1.40
ShortableNo LT Debt/Eq0.00 EarningsMar 14 Payout- Avg Volume9.76M Price1.39
Recom3.20 SMA2014.73% SMA508.34% SMA200-90.54% Volume2,021,135 Change-0.71%
19-Mar-13Downgrade MLV & Co Hold → Sell $0.50
25-Feb-13Downgrade Stifel Nicolaus Buy → Hold
25-Feb-13Downgrade Robert W. Baird Outperform → Neutral $30 → $4
25-Feb-13Downgrade MLV & Co Buy → Hold
21-May-12Reiterated MLV & Co Buy $12 → $21
08-May-12Downgrade WBB Securities Strong Buy → Buy $9 → $17
27-Sep-11Upgrade WBB Securities Buy → Strong Buy $8
11-Mar-11Upgrade Auriga U.S.A Hold → Buy $5 → $10
23-Nov-10Upgrade MLV Capital Hold → Buy $12
22-Nov-10Initiated WBB Securities Buy $8
11-Oct-10Reiterated Auriga U.S.A Hold $9 → $5
04-Oct-10Reiterated Argus Buy $30 → $15
21-Jun-10Downgrade Auriga U.S.A Buy → Hold $36 → $9
16-Apr-10Initiated Auriga U.S.A Buy $36
12-Mar-10Initiated Piper Jaffray Overweight
06-Oct-09Upgrade Argus Hold → Buy $30
24-Sep-08Initiated Stanford Research Buy $29
30-Jul-08Downgrade UBS Buy → Neutral
02-Jul-08Initiated Robert W. Baird Outperform $25
14-Mar-08Reiterated RBC Capital Mkts Outperform $40 → $30
24-May-13 01:43PM  Commit To Buy Affymax At $1, Earn 45.8% Annualized at TheStreet
22-May-13 02:18PM  Amag slumps on Ferahame recall in Switzerland AP
17-May-13 01:04PM  AFFYMAX INC Financials EDGAR Online Financials -6.99%
14-May-13 11:04PM  AFFYMAX INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Change in Directors or Principal Office EDGAR Online +8.40%
09:51AM  AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers EDGAR Online
13-May-13 01:34PM  Monday Sector Leaders: Biotechnology, Drugs at Forbes
10-May-13 06:02PM  Most active Nasdaq-traded stocks AP -24.86%
01:20PM  Most active Nasdaq-traded stocks AP
09-May-13 06:03PM  Most active Nasdaq-traded stocks AP +25.69%
05:32PM  Affymax says may be unable to continue operations theflyonthewall.com
01:25PM  4 Hot Stocks to Trade (or Not) at TheStreet
01:21PM  Most active Nasdaq-traded stocks AP
09:48AM  AFFYMAX INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08-May-13 06:03PM  Most active Nasdaq-traded stocks AP +25.22%
01:28PM  Most active Nasdaq-traded stocks AP
07-May-13 06:02PM  Most active Nasdaq-traded stocks AP +43.75%
03:01PM  Most active Nasdaq-traded stocks AP
02:49PM  Affymax Could Be The Best Reversal Play For 2013 at Seeking Alpha
28-Apr-13 02:00PM  Glancy Binkow & Goldberg Encourages Investors to Inquire About a Lead Plaintiff Position in the Class Action Lawsuit Against Affymax, Inc. -- AFFY GlobeNewswire
26-Apr-13 01:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and Upcoming Deadline -- AFFY GlobeNewswire
25-Apr-13 10:00PM  AFFYMAX 96 HOUR SHAREHOLDER ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Large Financial Interests of Important Deadline in Lawsuit Against Affymax, Inc. Business Wire
23-Apr-13 07:10PM  Sales disappoint, but tax gain lifts Amgen profit AP +6.19%
06:57PM  Law Offices of Todd M. Garber Announces Lead Plaintiff Deadline in the Class Action Lawsuit against Affymax, Inc. Business Wire
06:09PM  Amgen 1Q profit up 21 pct. on lower taxes AP
05:33PM  Amgen 1Q profit up 21 pct on lower taxes, expenses AP
03:02PM  UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and the Deadline of April 29, 2013 to Seek a Lead Plaintiff Position PR Newswire
09:16AM  AFFYMAX INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
22-Apr-13 09:42AM  Amgen Reporting Earnings In Wake Of Big Stock Run at Investor's Business Daily
19-Apr-13 01:21PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and Upcoming Deadline -- AFFY GlobeNewswire
12:07PM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and the Deadline of April 29, 2013 to Seek a Lead Plaintiff Position Business Wire
06:27AM  Earnings Preview: Amgen reports 1Q results Tuesday AP
12-Apr-13 09:36PM  Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Affymax, Inc. Business Wire -5.41%
11-Apr-13 08:26AM  Affymax says considering all alternatives, including bankruptcy theflyonthewall.com
10-Apr-13 01:12PM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and the Deadline of April 29, 2013 to Seek a Lead Plaintiff Position Business Wire
10:18AM  AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers EDGAR Online
06-Apr-13 06:00AM  Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Affymax, Inc. Business Wire
05-Apr-13 06:56PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and Upcoming Deadline -- AFFY GlobeNewswire
02:40PM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and the Deadline of April 29, 2013 to Seek a Lead Plaintiff Position Marketwired
02:40PM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and the Deadline of April 29, 2013 to Seek a Lead Plaintiff Position Marketwire
01:04PM  AFFYMAX INC Financials EDGAR Online Financials
04-Apr-13 07:00PM  Squitieri & Fearon, LLP Pursues Claims Against Affymax, Inc. -- AFFY GlobeNewswire
09:06AM  AFFYMAX INC Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
03-Apr-13 04:52PM  Harwood Feffer LLP Announces Investigation of Affymax, Inc. PR Newswire -7.20%
04:26PM  More Bio-Run Up Ideas at Seeking Alpha
02-Apr-13 11:07PM  Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Affymax, Inc. Business Wire -8.09%
04:58PM  Upcoming Lawsuits Will Likely Leave Affymax Shareholders With Nothing at Seeking Alpha
04:34PM  VIX - Options Volatility And Market Sonar: Tuesday Recap at Seeking Alpha
04:27PM  4 Healthcare Stock Stories Prescribed for Investors at Wall St. Cheat Sheet
11:48AM  Affymax Earnings:Heres Why the Stock is Falling Now at Wall St. Cheat Sheet
11:48AM  Will Affymaxs Loss Annoy These Top Institutional Shareholders? at Wall St. Cheat Sheet
08:52AM  The Week Ahead Could Be Pivotal For These Small Cap Companies' Stocks at Seeking Alpha
06:48AM  InPlay: Affymax misses by $1.24, reports revs in-line Briefing.com
06:45AM  Affymax Reports Fourth Quarter and Year-End 2012 Financial Results Business Wire
12:00AM  AFFYMAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
01-Apr-13 11:13PM  AFFYMAX INC Files SEC form 10-K, Annual Report EDGAR Online
01:03PM  [video] Deadline for Filing New and Past Tax Returns Looms at MarketWatch
11:17AM  [video] Deadline to Amending Past Tax Returns Looms at MarketWatch
31-Mar-13 01:00PM  Health Care's Sweet 16 Stocks: Gilead vs. Amgen at Motley Fool
28-Mar-13 01:08PM  Is It The End Of The Road For Affymax? at Seeking Alpha +11.29%
11:04AM  3 Reasons Investors Are Scared of Biotech Stocks at Motley Fool
27-Mar-13 11:09AM  The Danger of the One-Hit Wonder at Motley Fool
01:48AM  Largest Nasdaq Short Interest Percent Increases as of March 15 at Bloomberg
25-Mar-13 05:02PM  Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Affymax, Inc. Business Wire
02:35PM  2 Drug Stocks Under $10 To Pick As Favorites at TheStreet
24-Mar-13 06:00AM  5 of Last Week's Biggest Losers at Motley Fool
22-Mar-13 06:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Affymax, Inc. of Class Action Lawsuit and Upcoming Deadline - AFFY GlobeNewswire
21-Mar-13 06:30PM  3 Ways You Can Be a Successful Biotech Investor at Motley Fool +17.46%
03:53PM  Amazon Beats Apple On This 'Buffett-esque' Metric, But It Still Faces Headwinds at Seeking Alpha
08:14AM  Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha
20-Mar-13 06:06PM  Most active Nasdaq-traded stocks AP +20.00%
01:31PM  Most active Nasdaq-traded stocks AP
12:00PM  Pharmaceuticals: Just What the Dow Ordered at Motley Fool
09:14AM  Affymax Will Rise Again at Seeking Alpha
08:13AM  Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha
19-Mar-13 07:52PM  Down 60%: Affymax Cuts to the Bone at Motley Fool -64.04%
06:03PM  Most active Nasdaq-traded stocks AP
04:13PM  Affymax to Cut 75% of Workforce Zacks
04:11PM  Affymax Falls After Firing 75% of Workers at Bloomberg
04:01PM  Stocks Mixed on Cyprus Uncertainty, Lululemon Exhibits Transparency Hot Stock Minute
03:54PM  4 Healthcare Stock Stories for Tuesday Investment Wellness at Wall St. Cheat Sheet
03:11PM  Affymax plunges after announcing job cuts AP
02:53PM  Movers roundup: Cardinal Health, Affymax AP
02:45PM  Bank of America Makes Executive Changes and 2 Other Heavily Traded Stocks at Wall St. Cheat Sheet
01:17PM  Most active Nasdaq-traded stocks AP
12:54PM  Affymax In Trouble at Seeking Alpha
12:02PM  The end seems near for Affymax after workforce is slashed at MarketWatch
11:54AM  Bank of America Sells Branches and 2 Hot Stocks to Watch at Wall St. Cheat Sheet
11:43AM  Affymax plunges after announcing job cuts AP
10:42AM  Liberty Media Acquires 27.3% In Charter Communications and 4 Other Hot Stocks at Wall St. Cheat Sheet
10:26AM  The Daily Docket: Judge Says Creditors Can Vote on Rival Plans for Ahern at The Wall Street Journal
10:06AM  Wall Street climbs, supported by housing market data Reuters
10:06AM  Wall Street Takes Cyprus Issue Seriously at New York Times
10:06AM  Wall Street Buoyed by Strength in Housing at New York Times
10:04AM  US STOCKS-Wall Street climbs, supported by housing market data at Reuters
09:57AM  Analysts: Apples Watch Will Help Grow Platform and 4 New Opinions Investors Must Read Now at Wall St. Cheat Sheet
08:57AM  Wall Street set to open higher after two-day decline Reuters
08:55AM  US STOCKS-Wall St set to open higher after 2-day decline at Reuters
08:31AM  DSW falls on weak results, outlook optionMONSTER
08:12AM  Affymax shares drop 55%, as job cuts announced at MarketWatch
08:04AM  Early Movers: EA, SKUL, LULU & More at CNBC
Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses. It offers OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has a strategic collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize OMONTYS; and a license, manufacturing, and supply agreement with Nektar Therapeutics AL Corporation to manufacture, develop, and commercialize OMONTYS. Affymax, Inc. was founded in 2001 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knapp Jeffrey HChief Commercial OfficerFeb 15Option Exercise7.092,32816,51720,453Feb 19 09:01 PM
Knapp Jeffrey HChief Commercial OfficerFeb 15Sale15.762,32836,68618,125Feb 19 09:01 PM
Knapp Jeffrey HChief Commercial OfficerJan 15Option Exercise14.056,66193,57319,786Jan 17 09:37 PM
Knapp Jeffrey HChief Commercial OfficerJan 15Sale21.256,661141,56013,125Jan 17 09:37 PM
Knapp Jeffrey HChief Commercial OfficerDec 17Option Exercise14.016,69493,78419,819Dec 19 06:37 PM
Knapp Jeffrey HChief Commercial OfficerDec 17Sale22.316,694149,31613,125Dec 19 06:37 PM
LAPORTE KATHLEENDirectorDec 14Option Exercise15.525,00077,5755,000Dec 18 06:05 PM
LAPORTE KATHLEENDirectorDec 14Sale22.725,000113,6000Dec 18 06:05 PM
Orwin John ACEODec 03Option Exercise6.6815,798105,475107,798Dec 04 07:16 PM
Orwin John ACEODec 03Sale24.2215,798382,62892,000Dec 04 07:16 PM
Venteicher RobertSVP, Technical OperationsNov 23Option Exercise5.838334,85625,827Nov 27 05:25 PM
Venteicher RobertSVP, Technical OperationsNov 23Sale24.0083319,99224,994Nov 27 05:25 PM
Knapp Jeffrey HChief Commercial OfficerNov 19Option Exercise21.741,00021,74014,125Nov 19 06:07 PM
Knapp Jeffrey HChief Commercial OfficerNov 19Sale23.001,00023,00013,125Nov 19 06:07 PM
Knapp Jeffrey HChief Commercial OfficerNov 15Option Exercise15.235,83388,85818,958Nov 19 06:07 PM
Knapp Jeffrey HChief Commercial OfficerNov 15Sale22.625,833131,94213,125Nov 19 06:07 PM
Venteicher RobertSVP, Technical OperationsNov 02Option Exercise9.711,19511,60926,189Nov 05 07:24 PM
Venteicher RobertSVP, Technical OperationsNov 02Sale23.631,19528,23824,994Nov 05 07:24 PM
Duliege Anne-MarieChief Medical OfficerNov 01Sale22.901,05624,18223,125Nov 05 07:25 PM
Venteicher RobertSVP, Technical OperationsOct 23Option Exercise5.838334,85625,827Oct 25 08:04 PM
Venteicher RobertSVP, Technical OperationsOct 23Sale25.7483321,44124,994Oct 25 08:04 PM
Venteicher RobertSVP, Technical OperationsOct 15Option Exercise24.7242,1731,042,67667,167Oct 16 09:19 PM
Knapp Jeffrey HChief Commercial OfficerOct 15Option Exercise17.5710,012175,89923,137Oct 16 09:20 PM
Knapp Jeffrey HChief Commercial OfficerOct 15Sale26.7110,012267,37013,125Oct 16 09:20 PM
Venteicher RobertSVP, Technical OperationsOct 15Sale27.0042,1731,138,67124,994Oct 16 09:19 PM
Venteicher RobertSVP, Technical OperationsOct 11Option Exercise24.8620,014497,55545,008Oct 12 07:47 PM
Venteicher RobertSVP, Technical OperationsOct 11Sale27.0020,014540,37824,994Oct 12 07:47 PM
Knapp Jeffrey HChief Commercial OfficerOct 10Option Exercise24.5014,100345,45028,139Oct 12 07:47 PM
Venteicher RobertSVP, Technical OperationsOct 10Option Exercise13.3750,911680,76975,905Oct 12 07:47 PM
Venteicher RobertSVP, Technical OperationsOct 10Sale24.6550,9111,254,80124,994Oct 12 07:47 PM
Duliege Anne-MarieChief Medical OfficerOct 10Sale24.009,704232,89623,125Oct 12 07:48 PM
Knapp Jeffrey HChief Commercial OfficerOct 10Sale25.9415,014389,45013,125Oct 12 07:47 PM
Venteicher RobertSVP, Technical OperationsOct 09Option Exercise15.0010,938164,07035,932Oct 09 07:56 PM
Knapp Jeffrey HChief Commercial OfficerOct 09Option Exercise21.7412,000260,88026,039Oct 09 07:55 PM
Knapp Jeffrey HChief Commercial OfficerOct 09Sale23.2412,000278,88014,039Oct 09 07:55 PM
Venteicher RobertSVP, Technical OperationsOct 09Sale23.0010,938251,57424,994Oct 09 07:56 PM
Venteicher RobertSVP, Technical OperationsOct 05Option Exercise10.9911,789129,56136,783Oct 09 07:56 PM
Orwin John ACEOOct 05Option Exercise6.9041,664287,482133,664Oct 09 07:42 PM
Orwin John ACEOOct 05Sale22.5041,664937,44092,000Oct 09 07:42 PM
Venteicher RobertSVP, Technical OperationsOct 05Sale22.0011,789259,35824,994Oct 09 07:56 PM
Venteicher RobertSVP, Technical OperationsOct 04Option Exercise10.991001,09925,094Oct 04 07:29 PM
Venteicher RobertSVP, Technical OperationsOct 04Sale22.001002,20024,994Oct 04 07:29 PM
Venteicher RobertSVP, Technical OperationsOct 02Option Exercise7.995084,05925,502Oct 04 07:29 PM
Venteicher RobertSVP, Technical OperationsOct 02Sale21.1450810,73924,994Oct 04 07:29 PM
Orwin John ACEOOct 01Option Exercise6.6011,63276,730103,632Oct 03 10:32 AM
Orwin John ACEOOct 01Sale21.0411,632244,73792,000Oct 03 10:32 AM
Knapp Jeffrey HChief Commercial OfficerSep 17Option Exercise14.506,66296,58520,701Sep 17 09:13 PM
Knapp Jeffrey HChief Commercial OfficerSep 17Sale20.756,662138,26914,039Sep 17 09:13 PM
Orwin John ACEOSep 13Option Exercise6.6548,997325,774140,997Sep 17 09:12 PM
Duliege Anne-MarieChief Medical OfficerSep 13Option Exercise6.0523,227140,51056,056Sep 17 09:12 PM
Knapp Jeffrey HChief Commercial OfficerSep 13Option Exercise18.8418,750353,25033,702Sep 17 09:13 PM
Knapp Jeffrey HChief Commercial OfficerSep 13Sale20.0019,663393,26014,039Sep 17 09:13 PM
Duliege Anne-MarieChief Medical OfficerSep 13Sale20.0023,227464,54032,829Sep 17 09:12 PM
Orwin John ACEOSep 13Sale20.0048,997979,94092,000Sep 17 09:12 PM
CROSS HERBChief Financial OfficerSep 05Option Exercise7.995,00039,95016,293Sep 07 04:32 PM
CROSS HERBChief Financial OfficerSep 05Sale18.505,00092,50011,293Sep 07 04:32 PM
Knapp Jeffrey HChief Commercial OfficerAug 20Option Exercise7.7518,750145,39336,519Aug 22 07:44 PM
Orwin John ACEOAug 20Option Exercise6.6548,996325,767140,996Aug 22 07:43 PM
Orwin John ACEOAug 20Sale17.5048,996857,43092,000Aug 22 07:43 PM
Knapp Jeffrey HChief Commercial OfficerAug 20Sale17.5021,567377,42314,952Aug 22 07:44 PM
Knapp Jeffrey HChief Commercial OfficerAug 15Option Exercise7.874,58436,09822,353Aug 15 06:48 PM
Knapp Jeffrey HChief Commercial OfficerAug 15Sale16.484,58475,53117,769Aug 15 06:48 PM
Knapp Jeffrey HChief Commercial OfficerAug 13Sale15.954,65974,31117,769Aug 15 06:48 PM
Orwin John ACEOAug 01Option Exercise5.831,1006,41393,100Aug 03 04:54 PM
Orwin John ACEOAug 01Sale16.311,10017,94192,000Aug 03 04:54 PM
CROSS HERBChief Financial OfficerJul 17Option Exercise6.2310,00062,30020,000Jul 17 08:48 PM
CROSS HERBChief Financial OfficerJul 17Sale17.0010,000170,00010,000Jul 17 08:48 PM
Knapp Jeffrey HChief Commercial OfficerJul 16Option Exercise7.874,58436,09827,012Jul 17 08:49 PM
Knapp Jeffrey HChief Commercial OfficerJul 16Sale16.294,58474,68122,428Jul 17 08:49 PM
CROSS HERBChief Financial OfficerJul 13Option Exercise5.1015,00076,50025,000Jul 17 08:48 PM
Orwin John ACEOJul 13Option Exercise5.832,20012,826110,700Jul 17 08:49 PM
Knapp Jeffrey HChief Commercial OfficerJul 13Option Exercise10.994,75252,22428,093Jul 17 08:49 PM
Knapp Jeffrey HChief Commercial OfficerJul 13Sale15.005,66584,97522,428Jul 17 08:49 PM
Orwin John ACEOJul 13Sale15.0018,700280,50092,000Jul 17 08:49 PM
CROSS HERBChief Financial OfficerJul 13Sale15.5015,000232,50010,000Jul 17 08:48 PM
Knapp Jeffrey HChief Commercial OfficerJun 15Option Exercise6.233,00018,69026,341Jun 19 07:54 PM
Knapp Jeffrey HChief Commercial OfficerJun 15Sale13.103,00039,30023,341Jun 19 07:54 PM
open in yahoo | open in reuters | open in google